Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

Clinical trial NCT05765955 · COMPLETED

Trial details

NCT number: NCT05765955
Sponsor: Poolbeg Pharma plc
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Influenza, Human

Start date: 2022-07-22
Primary completion: 2022-12-14
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.